TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03064113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 700 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 700 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 700 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 700 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 350 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 350 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 350 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 350 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 μg
Study: NCT00637403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
Study: NCT02228005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Protocolized titration from 50 to max 200mg based on response and tolerance.
Study: NCT01042418

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect of breakfasts with whole vs milled rye kernels on appetite
Description: Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Effect of breakfasts with whole vs milled rye kernels on appetite
Description: Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of breakfasts with whole vs milled rye kernels on appetite
Description: Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
Study: NCT03708471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Description: This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic surgical ablation
Description: This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
Study: NCT03977012

Intervention type: DRUG
Intervention: Buprenorphine
Description: 5\~20 mcg
Study: NCT03089476

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluating atopy in infants
Description: This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluating TEWL and STS in adults
Description: This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
Study: NCT00532545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide 20 micrograms/daily subcutaneously
Study: NCT01831869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-thyroxine
Study: NCT03108612

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Análisis de carga de trabajo (ACT)
Description: Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
Study: NCT01023204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
Study: NCT00297648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
Study: NCT02882334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finger Force Manipulandum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Study: NCT04060953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life Report
Description: Subject report and interpretation guide based on SPADE cluster scores
Study: NCT02277353

Intervention type: OTHER
Intervention: Fluid loading to evaluate fluid responsiveness
Description: loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
Study: NCT01346332

Intervention type: DEVICE
Intervention: Iontophoresis System with Headset
Description: Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
Study: NCT02127606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration with tilt-table standing
Study: NCT00954967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
Study: NCT00750802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: 10mg Capsule, oral, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: 40mg Capsule, oral, single-dose
Study: NCT00998699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xoma 052
Description: Sterile solution subcutaneously administered every 4 weeks for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution subcutaneously administered every 4 weeks for 12 weeks
Study: NCT00750802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 2mg tablet, oral single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02634073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol
Description: It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol
Description: It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol
Description: It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
Study: NCT02764008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml %0,25 bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml %0,25 bupivacaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT01531465

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Function Testing & esophageal pressure monitoring
Description: Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary function testing and esophageal pressure
Description: Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
Study: NCT03445195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam-ETX2514
Description: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 1g IV solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imipenem-cilastatin
Description: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Description: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
Study: NCT04677062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-328
Description: Patients with GV-328 treatment
Study: NCT03199248

Intervention type: PROCEDURE
Intervention: Aspiration with percutaneous capsulotomy For digital mucous cysts
Description: The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.

Intervention type: PROCEDURE
Intervention: Aspiration with percutaneous capsulotomy For digital mucous cysts
Description: The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
Study: NCT05375500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine digital therapeutic
Description: digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
Study: NCT00918983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: Single intraprostatic injection of 2.5 mg NX-1207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic injection of placebo
Study: NCT03212040

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: needle biopsy
Description: breast biopsy using different needle gauges

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: needle biopsy
Description: breast biopsy using different needle gauges
Study: NCT02765152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discrete movement training group
Description: Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic movement training group
Description: Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
Study: NCT03118934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B multifocal contact lenses
Description: Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A multifocal contact lenses
Description: Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A multifocal contact lenses
Description: Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
Study: NCT04536662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
Study: NCT01668836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1 pill daily containing 500 mg/d of resveratrol for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1 pill daily containing 500 mg/d of resveratrol for 30 days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Diet of 1000kcal per day for 30 days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Diet of 1000kcal per day for 30 days
Study: NCT00972959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
Study: NCT03625726

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Thrombin generation assay (in vitro)
Description: One blood sample.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombin generation assay (in vitro)
Description: One blood sample.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Thrombin generation assay (in vitro)
Description: One blood sample.
Study: NCT03016169

Intervention type: DEVICE
Group type: OTHER
Intervention: Trifecta GT (Glide Technology) Valve
Description: Surgical aortic valve replacement with Trifecta GT Valve.
Study: NCT00908765

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 1. High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~2. Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 1. High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~2. Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
Study: NCT03351712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-Based Intervention and Activity Tracker WITH Feedback
Description: Combining ACT and Behavioral Change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gold Standard Intervention + Activity Tracker WITHOUT Feedback
Description: Medical Rehabilitation, Motivational Support and Psycho-Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Standard Intervention and Activity Tracker WITH Feedback
Description: Behavioral Change Condition - Activity Tracker

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-Based Intervention and Activity Tracker WITHOUT Feedback
Description: ACT-Based Intervention Standalone
Study: NCT04552613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: (A) Standard programme group, EGFR-TKI targeted therapy;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)
Description: (B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
Study: NCT00721409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
Study: NCT02977793

Intervention type: DEVICE
Intervention: Tomey EM-4000 Specular Microscope

Intervention type: DEVICE
Intervention: Tomey EM-4000 Specular Microscope

Intervention type: DEVICE
Intervention: Tomey EM-4000 Specular Microscope

Intervention type: DEVICE
Intervention: Konan CellChek XL Specular Microscope